Novavax (NVAX): NVAX can produce a vaccine from an emergent strain of flu virus in 12 weeks according to the CEO. Currently in Phase II trials, the FDA could give then emergency authorization power

BioCryst Pharmaceuticals (BCRX): BCRX is currently in Phase I testing (thus highly unlikely to get authorization power from the FDA) for drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.

AVI Biopharma (AVII): AVII is in the process with a joint venture with the Department of Defense’s Transformational Medical Technologies Initiative, with the goal of developing drugs for cardiovascular diseases.

Dynavax Technologies (DVAX): DVAX is currently in Phase II testing of its universal flu vaccine, the company also has several other drugs in its pipeline, and joint ventures with GlaxoSmithKline (GSK), Astra Zeneca, and Novartis. DVAX has $1.7 in cash per share, and no debt.

Sinovac Biotech (SVA): SVA is a Chinese based biotech company that engages in the sale of vaccines that protect against human infectious in mainland China. The company’s principal drug ‘Anflu’ provides a split virus influenza vaccine.

Advanced Life Sciences Holdings (ADLS): ADLS’s leading drug called ‘Cethromycin’ is a once-a-day treatment for pneumonia. Currently under review by the FDA, ADLS has tested Cethromycin in Phase III testing.

Quidel Corp (QDEL): QDEL makes the QuickVue test which is used during flu season. Recently the company reported a wider then expected loss because of a mild flue season, which led to weak demand for their flu test kit.

Generex Biotechnology (GNBT): GNBT operates several different sprays for weight-loss, and type I and type II diabetes. GNBT is also working on Phase I and Phase II testing for SARS, and Influenza.